ChineseChina UKUK DeutschlandDeutschland FranceFrance РоссияРоссия 한국한국 ไทยไทย Việt NamViệt Nam العربيةالعربية ҚазақстанҚазақстан EspañaEspaña MyanmarMyanmar DaiDai

Linking China’s Premium Healthcare · Serving Global Health Needs

Breaking down language, channel and process barriers in cross-border care — making the best doctors your personal doctors.
300 Grade-A partner hospitals · 3,000+ leading experts · one-stop service across all specialties

One-Stop Medical Care in China

  • International flights · Airport pickup · Nearby hotels
  • Multilingual interpreters · Full medical escort
  • Expert matching · Hospital fast-track
  • Full-cycle treatment · Post-op follow-up
Sign in

HHV8 is associated with multiple centers related to Castleman disease.

HHV8 Multi-Centered Disease Outline B-cell lymphoma related to Castleman's disease is a dubious disease in the field of blood tumors, clinical performance is complex and often involves multi-system congestion. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.

The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of multiple centers for HHV8 associated with Castleman's disease requires individualized treatment regimens, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, with the development of therapeutic-focused, immune-regulating treatments and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.

Treatment needs to closely monitor efficacy and adverse reactions, adjusting regimens in a timely manner depending on conditions. Multidisciplinary collaboration (MDT) is especially important for the comprehensive management of multiple centers for HHV8 related to Castleman's disease. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology to provide the following services to patients: 1.

Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4.

Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.